Stable patient with heart failure - the fact or the myth?

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• Heart failure (HF) patients with stable, mild symptoms (NYHA Class I-II) are often considered to have a good prognosis.
• However, registries and trials indicate a significant risk of mortality and hospitalization in these patients.
• Left ventricular remodeling and dysfunction persist even with minimal symptoms.

Purpose of the Study:

• To emphasize the necessity of continuous guideline-directed medical therapy (GDMT) in stable heart failure patients.
• To highlight the risks associated with under-treatment and suboptimal medication dosing in HF management.
• To advocate for comprehensive risk evaluation and individualized treatment strategies in heart failure care.

Main Methods:

• Analysis of data from HF registries (e.g., ESC-HF-LT-R, QUALIFY) and randomized trials (e.g., CHARM, EMPHASIS-HF, PARADIGM-HF, TRED-HF).
• Evaluation of clinical outcomes, echocardiographic parameters, and laboratory markers (e.g., N-terminal pro-B-type natriuretic peptide).
• Assessment of adherence to current HF treatment guidelines and medication optimization.

Main Results:

• Withdrawal of GDMT in asymptomatic HF patients led to clinical deterioration, despite improved echocardiographic and laboratory parameters (TRED-HF).
• A minority of HF patients are treated according to guidelines, with suboptimal medication doses (QUALIFY, ESC-HF-LT-R).
• Inadequate treatment significantly worsens patient prognosis.

Conclusions:

• Chronic, guideline-directed therapy is essential for heart failure patients, irrespective of symptom severity or apparent normalization of heart function.
• Validated risk assessment scales (e.g., MAGGIC) should be used for all HF patients.
• Individualized treatment incorporating novel drugs (e.g., sacubitril/valsartan) alongside standard therapies is crucial for optimizing HF management and patient outcomes.